Zafgen Company Profile (NASDAQ:ZFGN)

About Zafgen

Zafgen logoZafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ZFGN
  • CUSIP:
Key Metrics:
  • Previous Close: $4.02
  • 50 Day Moving Average: $4.07
  • 200 Day Moving Average: $3.49
  • 52-Week Range: $27,332,000.00 - $2.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.81
  • P/E Growth: 0.00
  • Market Cap: $107.96M
  • Outstanding Shares: 27,332,000
  • Beta: -1.24
Profitability:
  • Return on Equity: -47.40%
  • Return on Assets: -43.01%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 12.49%
  • Quick Ratio: 12.50%
Additional Links:
Companies Related to Zafgen:

Analyst Ratings

Consensus Ratings for Zafgen (NASDAQ:ZFGN) (?)
Ratings Breakdown: 3 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $18.80 (375.95% upside)

Analysts' Ratings History for Zafgen (NASDAQ:ZFGN)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016FBR & CoReiterated RatingHoldView Rating Details
8/25/2016Cowen and CompanyReiterated RatingBuy$60.00View Rating Details
7/21/2016Canaccord GenuitySet Price TargetHold$7.00 -> $4.00View Rating Details
7/20/2016Leerink SwannReiterated RatingMarket Perform$6.00View Rating Details
4/5/2016Royal Bank of CanadaReiterated RatingOutperform$19.00View Rating Details
2/20/2016SunTrust Banks, Inc.Reiterated RatingHold$7.00View Rating Details
10/16/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
(Data available from 2/26/2015 forward)

Earnings

Earnings History for Zafgen (NASDAQ:ZFGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
5/10/2016Q116($0.74)($0.65)ViewListenView Earnings Details
3/9/2016Q415($0.80)($0.85)ViewN/AView Earnings Details
11/10/2015Q3($0.79)($0.73)$80.60 million$78.20 millionViewListenView Earnings Details
8/11/2015Q215($0.71)($0.66)ViewListenView Earnings Details
5/12/2015Q115($0.52)($0.53)ViewListenView Earnings Details
3/19/2015Q414($0.84)($0.48)ViewListenView Earnings Details
11/11/2014Q314($0.87)($0.65)ViewN/AView Earnings Details
8/13/2014Q214($0.28)($2.96)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Zafgen (NASDAQ:ZFGN)
Current Year EPS Consensus Estimate: $-2.24 EPS
Next Year EPS Consensus Estimate: $-2.18 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.75)($0.75)($0.75)
Q2 20162($0.66)($0.62)($0.64)
Q3 20162($0.76)($0.68)($0.72)
Q4 20162($0.89)($0.69)($0.79)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Zafgen (NASDAQ:ZFGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Zafgen (NASDAQ:ZFGN)
Insider Ownership Percentage: 20.30%
Institutional Ownership Percentage: 50.64%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Frances K HellerDirectorBuy10,000$3.23$32,300.00View SEC Filing  
11/15/2016Frances K HellerDirectorBuy10,000$3.54$35,400.00View SEC Filing  
8/29/2016Thomas E HughesInsiderBuy10,000$3.00$30,000.00View SEC Filing  
7/26/2016Patricia L. AllenCFOBuy16,000$3.12$49,920.00View SEC Filing  
7/22/2016Frances K HellerDirectorBuy10,000$2.99$29,900.00View SEC Filing  
7/22/2016Thomas E. HughesInsiderBuy5,000$3.02$15,100.00View SEC Filing  
2/12/2016James E FlynnInsiderBuy64,545$6.25$403,406.25View SEC Filing  
2/11/2016James E FlynnInsiderBuy267,493$6.02$1,610,307.86View SEC Filing  
9/24/2015Kevin P StarrDirectorSell136,579$43.90$5,995,818.10View SEC Filing  
9/18/2015Avi Y GoldbergDirectorSell5,000$45.00$225,000.00View SEC Filing  
9/18/2015Thomas E. HughesCEOSell45,626$42.53$1,940,473.78View SEC Filing  
9/17/2015Dennis D. KiminsiderSell39,407$40.00$1,576,280.00View SEC Filing  
6/10/2015Avi Y GoldbergDirectorSell3,000$35.00$105,000.00View SEC Filing  
6/1/2015Avi Y GoldbergDirectorSell2,000$32.23$64,460.00View SEC Filing  
6/19/2014Alicia SecorInsiderBuy4,000$20.00$80,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Zafgen (NASDAQ:ZFGN)
DateHeadline
News IconLooking at the Numbers for Zafgen, Inc. (NASDAQ:ZFGN) - SKV News (NASDAQ:ZFGN)
skvnews.com - February 25 at 4:39 AM
News IconFocusing the Lens on Zafgen, Inc. (NASDAQ:ZFGN) Earnings & Projections - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 25 at 4:39 AM
News IconEquity Focus: Looking at Shares of Zafgen Inc (ZFGN) - Rives Journal (NASDAQ:ZFGN)
rivesjournal.com - February 24 at 12:41 AM
News IconAnalysts Take: Zafgen, Inc. (NASDAQ:ZFGN) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:ZFGN)
aikenadvocate.com - February 24 at 12:41 AM
News IconAnalysts Peeling Back The Layers on Zafgen, Inc. (NASDAQ:ZFGN): Consensus Take - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 24 at 12:41 AM
News IconMarket Review: Indicator Watch for Zafgen Inc (ZFGN) - Davidson Register (NASDAQ:ZFGN)
davidsonregister.com - February 22 at 10:51 AM
News IconZafgen, Inc. (NASDAQ:ZFGN) Earnings At A Glance: Consensus Projections in Spotlight - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 22 at 10:51 AM
News IconInsider Alert: Zafgen, Inc. (NASDAQ:ZFGN) Notable Insider Activity - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 21 at 8:02 AM
News IconZafgen Inc ZFGN Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:ZFGN)
www.bioportfolio.com - February 18 at 7:45 PM
News IconEarnings at a Glance For Zafgen, Inc. (NASDAQ:ZFGN): What Are Analysts Predicting For the Stock? - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 18 at 11:07 AM
News IconPeeling Back The Layers on Zafgen, Inc. (NASDAQ:ZFGN): Analysts & Street Weigh In - Winfield Review (NASDAQ:ZFGN)
winfieldreview.com - February 15 at 7:05 AM
finance.yahoo.com logoZafgen to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ZFGN)
finance.yahoo.com - February 10 at 6:50 AM
News IconStock Tripped Up Out of The Gate: Zafgen, Inc. (NASDAQ:ZFGN) - Aiken Advocate (NASDAQ:ZFGN)
aikenadvocate.com - February 7 at 4:19 PM
News IconAre Insiders Bumping Up Their Positions in Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 31 at 8:17 AM
News IconHigh Volatility Moving the Needle For Shares of Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 31 at 8:17 AM
News IconPeeling Back The Layers on Zafgen, Inc. (NASDAQ:ZFGN): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 31 at 8:17 AM
News IconZafgen Inc ZFGN Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 19122016] Prices from USD $250 (NASDAQ:ZFGN)
www.bioportfolio.com - January 30 at 1:51 AM
News IconCCI, ADX, and Williams %R Review for Zafgen Inc. (ZFGN) - Rives Journal (NASDAQ:ZFGN)
rivesjournal.com - January 29 at 7:21 AM
News IconIndicator Level Summary for Zafgen Inc. (ZFGN) - Sherwood Daily (NASDAQ:ZFGN)
sherwooddaily.com - January 27 at 4:19 PM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 27 at 6:58 AM
News IconStock Update: Estimates & Target in Focus for Zafgen, Inc. (NASDAQ:ZFGN) - Aiken Advocate (NASDAQ:ZFGN)
aikenadvocate.com - January 27 at 6:58 AM
News IconTrading Sheet: Tracking Technicals for Zafgen Inc. (ZFGN) - Sherwood Daily (NASDAQ:ZFGN)
sherwooddaily.com - January 24 at 4:02 PM
News IconZafgen, Inc. (NASDAQ:ZFGN) Quarterly EPS Projection At $-0.57 - Stock Observer (NASDAQ:ZFGN)
www.thestockobserver.com - January 24 at 4:02 PM
News IconAnalysts Pounding The Pavement on Zafgen, Inc. (NASDAQ:ZFGN): Consensus Update - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 24 at 4:02 PM
News IconMA Watch on Shares of Zafgen Inc. (ZFGN) - Rives Journal (NASDAQ:ZFGN)
rivesjournal.com - January 21 at 6:16 AM
News IconAnalysts Pull Back the Curtain on Zafgen, Inc. (NASDAQ:ZFGN): Consensus Update - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 21 at 6:16 AM
News IconSell-side Consensus Sees Zafgen, Inc. (NASDAQ:ZFGN) Going Where Near-Term? - Aiken Advocate (NASDAQ:ZFGN)
aikenadvocate.com - January 19 at 4:35 PM
News IconEarnings Fever Sweeping In, What Are Analysts Expecting From Zafgen, Inc. (NASDAQ:ZFGN)? - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 18 at 6:33 AM
News IconTracking Corporate Insiders: What Are They Doing With Zafgen, Inc. (NASDAQ:ZFGN) - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 17 at 8:12 AM
News IconNews Impact Score Of Zafgen, Inc. (NASDAQ:ZFGN) Set At 0 - Stock Observer (NASDAQ:ZFGN)
www.thestockobserver.com - January 16 at 9:52 PM
News IconWill The Needle Move For Zafgen, Inc. (NASDAQ:ZFGN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 16 at 9:52 PM
News IconPrimed For An Earnings Beat? Sell-side Chimes in on Zafgen, Inc. (NASDAQ:ZFGN) Stock - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 13 at 8:34 PM
News IconWall Street and Armchair Analysts Weigh in on Zafgen, Inc. (NASDAQ:ZFGN) Heading Into The New Year - Wall Street Beacon (NASDAQ:ZFGN)
wsbeacon.com - January 13 at 7:41 AM
istreetwire.com logoTraders Recap: Zafgen, Inc. (ZFGN), Symantec Corporation (SYMC), Cabot Oil & Gas Corporation (COG) - iStreetWire (NASDAQ:ZFGN)
istreetwire.com - January 9 at 3:28 PM
News IconAnalyst Outlook on Rating and Recommendation: Zafgen Inc (NASDAQ:ZFGN) - Post Registrar (NASDAQ:ZFGN)
postregistrar.com - January 9 at 3:28 PM
News IconZafgen, Inc. (NASDAQ:ZFGN) News Impact Score At 10 | Stock ... - Stock Observer (NASDAQ:ZFGN)
www.thestockobserver.com - January 9 at 5:22 AM
marketexclusive.com logoAnalyst Upgrades – Zafgen (NASDAQ:ZFGN) Stock Gets Upgraded By JMP Securities from Underperform to Market ... - Market Exclusive (NASDAQ:ZFGN)
marketexclusive.com - January 8 at 6:45 AM
marketexclusive.com logoAnalyst Activity – FBR & Co Reiterates Hold on Zafgen (NASDAQ:ZFGN) (NASDAQ:ZFGN)
marketexclusive.com - January 7 at 6:37 AM
rttnews.com logoZafgen Inc. (ZFGN) Has Surged To Over A 5-Month High (NASDAQ:ZFGN)
www.rttnews.com - January 7 at 6:37 AM
finance.yahoo.com logoZafgen upgraded by JMP Securities (NASDAQ:ZFGN)
finance.yahoo.com - January 7 at 6:37 AM
investornewswire.com logoZafgen, Inc. (NASDAQ:ZFGN) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:ZFGN)
www.investornewswire.com - December 27 at 3:31 PM
News IconTrading Views: RSI, MA, and ADX Review for Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 14 at 8:57 PM
News IconTracking Williams %R for Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 13 at 4:08 PM
News IconNews Impact Score Of Zafgen, Inc. (NASDAQ:ZFGN) At 0 - Stock Observer (NASDAQ:ZFGN)
www.thestockobserver.com - December 12 at 8:00 AM
News IconWhat are the Technical Charts Saying About Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 11 at 8:00 AM
News IconTrading Scope: Indicator Review for Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 8 at 8:23 PM
News IconLooking at the Technicals for Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 8 at 3:20 PM
News IconDirectional Index Update on Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 6 at 8:00 AM
News IconWhat are the Levels Showing for Shares of Zafgen Inc. (ZFGN) - StockTalk Daily (NASDAQ:ZFGN)
stocktalkdaily.com - December 3 at 7:38 PM
News IconChart Watch: Following Indicators on Shares of Zafgen Inc. (ZFGN) - Yankee Analysts (NASDAQ:ZFGN)
yankeeanalysts.com - December 2 at 9:07 PM

Social

What is Zafgen's stock symbol?

Zafgen trades on the NASDAQ under the ticker symbol "ZFGN."

Where is Zafgen's stock going? Where will Zafgen's stock price be in 2017?

5 analysts have issued 12 month price targets for Zafgen's shares. Their predictions range from $4.00 to $60.00. On average, they expect Zafgen's share price to reach $18.80 in the next twelve months.

When will Zafgen announce their earnings?

Zafgen is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

What are analysts saying about Zafgen stock?

Here are some recent quotes from research analysts about Zafgen stock:

  • According to Zacks Investment Research, "Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts. " (1/12/2017)

  • FBR & Co analysts commented, "On March 9 after the close, Zafgen held a conference call to discuss its 4Q15 financial results and provide an update on the future development path for beloranib. As a reminder, beloranib was placed on full clinical hold following two patient deaths due to pulmonary embolism (PE) and an asymmetry of thromboembolic events in patients treated with the study drug. From the call, we highlight three key takeaways: (1) Positive data from two clinical trials, ZAF-311 and ZAF-203, in patients with Prader-Willi syndrome (PWS) and severe obesity, respectively, strengthen the overall data package for beloranib’s future use in patients with PWS; (2) Zafgen remains focused on preparing its risk mitigation package for the FDA; and (3) management offered three potential scenarios for beloranib’s use in patients with PWS. Overall, we believe the data generated from beloranib in PWS and severe obesity patients provide a compelling rationale for its use in PWS, if the therapy can be safely administered." (3/11/2016)

Who owns Zafgen stock?

Zafgen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (14.89%), Foresite Capital Management II LLC (2.43%), Royce & Associates LP (1.84%), Artal Group S.A. (1.83%), Foresite Capital Management III LLC (1.72%) and State Street Corp (1.29%). Company insiders that own Zafgen stock include Avi Y Goldberg, Dennis D Kim, Frances K Heller, James E Flynn, Kevin P Starr, Patricia L Allen and Thomas E Hughes.

Who sold Zafgen stock? Who is selling Zafgen stock?

Zafgen's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management II LLC, AQR Capital Management LLC, Foresite Capital Management III LLC and FT Options LLC.

Who bought Zafgen stock? Who is buying Zafgen stock?

Zafgen's stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Dimensional Fund Advisors LP, Federated Investors Inc. PA and State Street Corp. Company insiders that have bought Zafgen stock in the last two years include Frances K Heller, James E Flynn, Patricia L Allen and Thomas E Hughes.

How do I buy Zafgen stock?

Shares of Zafgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Zafgen stock cost?

One share of Zafgen stock can currently be purchased for approximately $3.95.

Zafgen (NASDAQ:ZFGN) Chart for Sunday, February, 26, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Earnings History Chart

Earnings by Quarter for Zafgen (NASDAQ:ZFGN)

Dividend History Chart

Dividend Payments by Quarter for Zafgen (NASDAQ:ZFGN)

Last Updated on 2/26/2017 by MarketBeat.com Staff